Eric K. Singhi, MD (@lungoncdoc) ranks #3 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 117 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: ADAURA, PAPILLON, LAURA. CMS Open Payments lists $60,613 in 2025 general payments.
At a Glance
- 25 posts naming a trial in 2026
- 17 trials discussed by name
- Lung Cancer: US #3, Global #4 · 117 physicians engaged
- Leading physician voice: #1 of 6 physicians on LAURA; #1 of 3 physicians on NeoADAURA
- Presented at WCLC 2026 in 2026
- CMS Open Payments lists $60,613 in 2025 general payments.
This Month
What Eric K. Singhi, MD has posted in the last 30 days. Updated November 10, 2026.
WOW! BIG news for our patients with extensive-stage small cell lung cancer! Phase 3 DeLLphi-305 trial, adding tarlatamab to durvalumab maintenance after initial chemoIO: ✅ OS: 21.1 vs 12.7 months (HR 0.42) ✅ PFS: 7.4 vs 1.9 months (HR 0.34) Practice-changed! #ESMO26 https://t.co/t23SBNzfUD
Who Amplifies Eric K. Singhi, MD
Physicians who reposted Eric K. Singhi, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #3 | #4 | 117 | 185 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Eric K. Singhi, MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · PosterReal-world treatment duration and outcomes among patients with early stage NSCLC receiving adjuvant osimertinib: a retrospective cohort studySource: @lungoncdoc on X ↗
What Colleagues Are Saying About Eric K. Singhi, MD
2026 posts by fellow physicians that mention @lungoncdoc, quoted word for word.
This is the treatment algorithm we have used to drive our 🗣️ with @lungoncdoc on targeted options in 1L for metastatic NSCLC! ✅ Zongertinib recently added ✅ Data around front line when you have multiple options ✅ Role of Re-testing #lcsm #OncTwitter @OncoAlert @OncUpdates https://t.co/k3Bf3SXVgp https://t.co/c2q1e8HvyI
Dr. @lungoncdoc takes us through the rapidly evolving space of HER2-mutated NSCLC. Great to have multiple innovations in the subsequent line space. Looking forward to moving these forward to the frontline together with innovative combination strategies. ##WinterLung26 @gotoPER https://t.co/nmFUehoyYP
Join @lungoncdoc at #WCLC26 today! Social media has become an important part of how patients learn about lung cancer, find expertise, and engage with care providers. This session will explore how to use it thoughtfully and effectively. @IASLC https://t.co/7lLe5gq2Wt
#WCLC26 Communication session now 🆙 @lungoncdoc provides a Patient Advocates’ Guide to Finding Meaningful Information via Social Media ▶️ See it ▶️ Verify it ▶️ Ask About it #lcsm https://t.co/lEqoryaJze
Managed to snap a quick 🤳 with @lungoncdoc at @IASLC #WCLC26! Thanks for sharing constant updates on social media and helping provide #education and debunking myths for the #LCSM community. https://t.co/sR3zklVJ3t
#WCLC26 Good morning 🇰🇷 @BalazsHalmosMD @NarjustFlorezMD @lungoncdoc @StephenVLiu @IASLC Enjoying sunrise here Enjoy sunset over ther https://t.co/aKcxEer7PC
Trials Eric K. Singhi, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| ADAURA | 5 | #2 of 41 | Sep 13, 2026 |
| PAPILLON | 3 | #3 of 26 | Sep 13, 2026 |
| LAURA | 2 | #1 of 6 | Oct 10, 2026 |
| NeoADAURA | 2 | #1 of 3 | Oct 10, 2026 |
| ARROS-1 | 2 | #6 of 26 | Sep 14, 2026 |
| WU-KONG28 | 2 | #4 of 29 | May 29, 2026 |
| DeLLphi-305 | 1 | #16 of 86 | Oct 24, 2026 |
| DESTINY-Lung04 | 1 | #3 of 37 | Sep 14, 2026 |
| REZILIENT3 | 1 | #10 of 27 | Sep 14, 2026 |
| MAVERICK (SWOG S1827) | 1 | #12 of 33 | Sep 12, 2026 |
| SigVie-002 (Be6A Lung-01) | 1 | #8 of 8 | Jun 22, 2026 |
| DeLLphi-304 | 1 | #7 of 23 | Jun 1, 2026 |
| LIBRETTO-432 | 1 | #6 of 53 | May 31, 2026 |
| HARMONi-6 | 1 | #8 of 74 | May 31, 2026 |
| CROWN | 1 | #5 of 36 | May 29, 2026 |
| CHRYSALIS-2 | 1 | #3 of 14 | May 29, 2026 |
| FLAURA2 | 1 | #13 of 25 | Mar 26, 2026 |
Eric K. Singhi, MD on ADAURA
8 YEARS later, and the ADAURA curves are still speaking. In resected EGFR+ NSCLC, adjuvant osimertinib continues to show a durable OS benefit: ▫️Stage II–IIIA: 74% v 58% 8-year OS (HR 0.53) ▫️Stage IB–IIIA: 79% vs 64% (HR 0.52) Long-term follow-up matters. #WCLC26 @IASLC https://t.co/phPwzmwkBg https://t.co/lwhi3nLitK
As we await the 8-year ADAURA update at #WCLC26, our study adds another piece of the story: Long-term outcomes matter. So does what happens during those 3 years of treatment… A thread… @IASLC @EGFRResisters https://t.co/Zwy0G85WTW
2/ We know ADAURA recommends a 3 year duration of osimertinib, but are patients really able to stay on for the whole time? https://t.co/mvYtj9uU5m
Eric K. Singhi, MD on PAPILLON
‼️PAPILLON OS: Crossover matters… 1L EGFR exon20ins NSCLC Ami + chemo v chemo: OS: 34.3 v 27.9 mo (HR 0.87) But 76% who progressed on chemo crossed over to ami. After adjusting for crossover: HR 0.57 (P=.003). Upfront ami may have a larger OS benefit than ITT suggests. https://t.co/p95llLyLpU https://t.co/3Otgdky7VG
@chulkimMD presents the OS update from PAPILLON: 1L amivantamab plus chemotherapy in EGFR exon 20 insertion NSCLC @IASLC #WCLC26 https://t.co/9Lgj5s4mqJ
How to choose between PAPILLON vs 1L Sunvozertinib given this NEW data? Our Dr. John Heymach says “toxicity profile” and “route of delivery” are the key factors for decision-making as of now. @ASCO #ASCO26 https://t.co/OdwHEUadLt
Eric K. Singhi, MD on LAURA
#DCLung26 Debate Starts NOW!! LAURA v NeoADAURA @JSabari @JuliaRotow @StephenVLiu @Joshua_Reuss https://t.co/JtpTybdFfx
Key differences to be aware of: LAURA vs NeoADAURA #DCLung26 @JSabari https://t.co/5eP5Rr8ifJ https://t.co/p9G5WRUq0p
Eric K. Singhi, MD on NeoADAURA
#DCLung26 Debate Starts NOW!! LAURA v NeoADAURA @JSabari @JuliaRotow @StephenVLiu @Joshua_Reuss https://t.co/JtpTybdFfx
Key differences to be aware of: LAURA vs NeoADAURA #DCLung26 @JSabari https://t.co/5eP5Rr8ifJ https://t.co/p9G5WRUq0p
Eric K. Singhi, MD on ARROS-1
For a single-arm study w/ still-maturing follow-up… 94% ORR + 90% 1-y PFS + strong CNS control is a compelling signal from ARROS-1. However, IMO taletrectinib is still the benchmark for frontline management. But ABSOLUTELY great to have more options for our patients. #WCLC26 https://t.co/wjHbATbyTC https://t.co/wnAGOqgoUj
@alexdrilon presents new #WCLC26 data in ROS1+ NSCLC from the ARROS-1 study, evaluating zidesamtinib in ROS1 TKI-naïve advanced NSCLC: ▫️ORR: 94% (88/94) ▫️CR: 15% ▫️Median DOR: not reached https://t.co/BBslgJ1CKy
Eric K. Singhi, MD on WU-KONG28
‼️ Phase 3 WU-KONG28: 1L Sunvozertinib v Chemotherapy in EGFR exon20 NSCLC ▫️mPFS 10.3 v 7.5 mos (HR 0.65) ▫️ORR ~60% v 30% Keep in mind, 1L PAPILLON (Amivantamab + chemo) is currently our SOC (mPFS 11.4 mos, ORR of 73%) #ASCO26 @ASCO https://t.co/oCkiYgrSuH
Our Dr. John Heymach @UTMDAnderson presents WU-KONG28 at #ASCO26: ✅ mPFS: 10.3 vs 7.5 mos (HR 0.65) ✅ ORR: 58.9% vs 31.1% ✅ DoR: 11.2 vs 7.1 mos 🔄 ~90% on chemo crossed over to sunvozertinib on study ⚠️ G3+ TRAEs: 61% (diarrhea any grade 84%, G3 13.5%) @ASCO https://t.co/EvnOplboEG https://t.co/c0LTVpGTeX
Eric K. Singhi, MD on DeLLphi-305
WOW! BIG news for our patients with extensive-stage small cell lung cancer! Phase 3 DeLLphi-305 trial, adding tarlatamab to durvalumab maintenance after initial chemoIO: ✅ OS: 21.1 vs 12.7 months (HR 0.42) ✅ PFS: 7.4 vs 1.9 months (HR 0.34) Practice-changed! #ESMO26 https://t.co/t23SBNzfUD
Eric K. Singhi, MD on DESTINY-Lung04
T-DXd trying to catch up in the frontline setting with zongertinib and sevabertinib Results from #DESTINYLung04…. #WCLC26 https://t.co/wb9BkFV7dg
Eric K. Singhi, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
#ASCO26 is almost here! Here are just a few of the lung cancer abstracts I’ll be watching closely this year! @ASCO https://t.co/m10rwTpy7Q
In case you missed it: real progress is happening in ALK+ NSCLC. And we are just getting started. Here’s to what’s next. @myESMO #ELCC26 https://t.co/2KvQF6nhOw https://t.co/NMsRO2WjMR
Nice summary slides of recent neoadjuvant treatment approaches for patients with early-stage, resectable EGFR+ NSCLC. But the key question remains: Will these modest pCR rates translate into meaningful long-term outcomes for our patients? @ASCO #ASCO26 https://t.co/saNCfaba9j
🚦 pCR + MRD in periop NSCLC: 🔴 MRD+ = worst prognosis ▫️Will adj IO be enough? 🟡 MRD– / no pCR (~80%) = gray zone ▫️Who actually benefits (and is IO ‘right’)? 🟢 pCR + MRD– = best prognosis ▫️Overtreatment risk v false-negative MRD #ELCC26 @myESMO https://t.co/r2j8od3nuI https://t.co/7Ii0ikOzsQ
Novel concept exploring how we can help the immune system recognize ALK resistance mutations BEFORE resistance develops on treatment! Fantastic work! @ALKPositiveinc @ASCO https://t.co/SGCRPk3LGQ
Industry Payments
CMS Open Payments · 2025 general payments
$60,613 across 62 payments